Clinical Trials Directory

Trials / Completed

CompletedNCT01716858

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia

Sulforaphane-rich Broccoli Sprout Extract for Schizophrenia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Chiba University · Academic / Other
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Accumulating evidence suggests a role of oxidative stress in the pathophysiology of schizophrenia. The potent antioxidant sulforaphane (SFN) is an organosulfur compound derived from a glucosinolate precursor found in cruciferous vegetables such as broccoli, Brussels sprouts and cabbage. The protection afforded by SFN is thought to be mediated via activation of the NF-E2-related factor-2 (Nrf2) pathway and subsequent up-regulation of phase II detoxification enzymes and antioxidant proteins, through an enhancer sequence referred to as the electrophilic responsive element or antioxidant responsive element. Recently, we reported that SFN could attenuate behavioral abnormalities in mice after the NMDA receptor antagonist phencyclidine. Considering the potent antioxidant effects of SFN, we have a hypothesis that SFN would be a potential therapeutic drug for schizophrenia. The purpose of this study is to determine whether SFN-rich broccoli sprout extract have beneficial effects in patients with schizophrenia.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSulforaphane-rich Broccoli Sprout Extract

Timeline

Start date
2012-10-01
Primary completion
2013-09-01
Completion
2014-03-01
First posted
2012-10-30
Last updated
2015-07-30

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT01716858. Inclusion in this directory is not an endorsement.